Clinical trials: Carcinoma of Vagina
Rectal Cancer, Ovarian Cancer
Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer
This is a single centre pilot trial to establish the feasibility and role of endoluminal HIFU in patients with locally advanced cancer within the pelvis that is either primary or recurrent and with all available current therapy…
- Conditions
- Rectal Cancer, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer
- Trial name
- NCT01097239
- Testing
- Sonablate 500 (High Intensity Focused Ultrasound (HIFU))
- Where
- United Kingdom
- Sponsor
- Imperial College London
Breast Carcinoma, Cancer Survivor
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
This pilot clinical trial studies how well fraction carbon dioxide (CO2) laser therapy works in treating vaginal atrophy in patients with breast cancer.
- Conditions
- Breast Carcinoma, Cancer Survivor, Cervical Carcinoma, Dyspareunia
- Trial name
- NCT03307044
- Testing
- Laser Therapy, Questionnaire Administration
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer
This trial studies the prevalence of anal dysplasia and anal cancer in patients with cervical, vaginal, and vulvar dysplasia and cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ, Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Trial name
- NCT02140021
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 409 people
- Sponsor
- M.D. Anderson Cancer Center
Human Papillomavirus Infection
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
This study is to evaluate the safety and tolerability profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) in healthy women ages 18-45
- Trial name
- NCT05680454
- Testing
- Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Anal Carcinoma, Bladder Carcinoma
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and…
- Conditions
- Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma
- Trial name
- NCT07118176
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Cancer Rectum, Cancer Vulva
Interventions for the Management of Perineal Cancer Pain
Pain associated with neoplasms may be of somatic, visceral, or neuropathic origin.Visceral pain or pain that is mediated by the sympathetic fibers in the perineal area associated with malignancy in the pelvis may be effectively…
- Conditions
- Cancer Rectum, Cancer Vulva, Cancer Vagina
- Trial name
- NCT06392399
- Testing
- cooled radiofrequency ,, conventional radiofrequency, neurolysis of ganglion
- Volunteers
- 60 people
- Sponsor
- Assiut University
Cervical Cancer, Uterine Cancer
Image-Guided Gynecologic Brachytherapy
This research is being done to evaluate multimodality imaging, including magnetic resonance imaging-guided therapy (MRT), as a possible treatment for gynecologic cancers.
- Conditions
- Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer
- Trial name
- NCT02993900
- Testing
- Image-Guided Brachytherapy
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HPV Infections, Cervical Cancer Stage IIa
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05027776
- Testing
- 2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years
- Where
- China
- Volunteers
- 1,348 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, Colorectal Cancer
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing radiation therapy to the pelvis. It is not yet known whether octreotide is effective for diarrhea.
- Conditions
- Cervical Cancer, Colorectal Cancer, Diarrhea, Endometrial Cancer
- Trial name
- NCT00033605
- Testing
- octreotide acetate, radiation
- Volunteers
- 130 people
- Sponsor
- Alliance for Clinical Trials in Oncology
HPV Infections, Cervical Cancer Stage IIa
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05371353
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Papillomavirus Infections, Uterine Cervical Neoplasms
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
This study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam.
- Conditions
- Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms
- Trial name
- NCT03546842
- Testing
- 9vHPV vaccine
- Where
- Vietnam
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Extramammary Paget's Disease, Extramammary Paget Disease
Gynecologic Extramammary Paget's Disease
In addition to evaluating treatment outcomes, tissue samples and swabs will be collected as part of this study to allow physicians to better understand Extramammary Paget's Disease (EMPD).
- Conditions
- Extramammary Paget's Disease, Extramammary Paget Disease, Paget Disease, Extramammary, Extramammary Paget's Disease of Vulva (Diagnosis)
- Trial name
- NCT03564483
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Ovarian Cancer Stage III, Ovarian Cancer Stage IV
Self-Advocacy Serious Game in Advanced Cancer
Self-advocacy, defined as the ability of a patient to get her needs and priorities met in the face of a challenge, is an essential skill but not all women with advanced cancer are able to do it.
- Conditions
- Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Breast Cancer Stage IV, Cervical Cancer Stage IIIB
- Trial name
- NCT03339765
- Testing
- Strong Together serious game
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- University of Pittsburgh
Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled.
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary
- Trial name
- NCT06730347
- Testing
- Lorigerlimab
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- MacroGenics
Gynecologic Cancer, Endometrial Cancer
3D Printed Custom Applicators for HDR BT (DISCO)
Intracavitary brachytherapy for gynaecological cancer currently use cylinder-type applicators or custom wax moulds to place a radioactive source in close proximity to the treatment area and provide highly conformal dose…
- Conditions
- Gynecologic Cancer, Endometrial Cancer, Vaginal Cancer, Vulva Cancer
- Trial name
- NCT06432478
- Testing
- 3D-printed custom applicator
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Royal North Shore Hospital